You are here

dry eye disease

Bausch + Lomb Buys J&J’s Dry Eye Drops for $106.5M in Expansion of OTC Business

Bausch + Lomb Buys J&J’s Dry Eye Drops for $106.5M in Expansion of OTC Business

BioSpace

dry eye disease

Flag link:

Bausch + Lomb to acquire Xiidra, ‘front of eye’ assets from Novartis

Bausch + Lomb to acquire Xiidra, ‘front of eye’ assets from Novartis

Healio

dry eye disease

Flag link:

FDA Approves Bausch + Lomb, Novaliq Dry Eye Disease Drug

FDA Approves Bausch + Lomb, Novaliq Dry Eye Disease Drug

BioSpace

dry eye disease

Flag link:

Aldeyra reports positive data from dry eye disease therapy trial

Aldeyra reports positive data from dry eye disease therapy trial

Clinical Trials Arena

Aldeyra Therapeutics

clinical trials

dry eye disease

Flag link:

Aldeyra’s sights set on November PDUFA

Aldeyra’s sights set on November PDUFA

Endpoints

Aldeyra Therapeutics

dry eye disease

Flag link:

Aurinia Pharma, Sun Pharma enter into settlement agreement for dry eye disease drug

Aurinia Pharma, Sun Pharma enter into settlement agreement for dry eye disease drug

Medical Dialogues

Aurinia Pharmaceuticals

dry eye disease

Flag link:

Iveric hits again in pivotal eye disease program, keeping it on Apellis' tail in race to market

Iveric hits again in pivotal eye disease program, keeping it on Apellis' tail in race to market

Fierce Biotech

Apellis Pharmaceuticals

clinical trials

dry eye disease

geographic atrophy

Flag link:

Oyster Point plows ahead with 50 layoffs to focus on approved eye drug

Oyster Point plows ahead with 50 layoffs to focus on approved eye drug

Fierce Biotech

Oyster Point Pharma

dry eye disease

Flag link:

Aldeyra says eye drop clears three dry eye signals en route to FDA

Aldeyra says eye drop clears three dry eye signals en route to FDA

Endpoints

Aldeyra Therapeutics

dry eye disease

clinical trials

Flag link:

Oyster Point Laying Off 50 with Focus on Dry Eye Drug Launch

Oyster Point Laying Off 50 with Focus on Dry Eye Drug Launch

BioSpace

Oyster Point Pharma

dry eye disease

Flag link:

Aldeyra Prepares to Submit Dry Eye Disease Treatment Reproxalap to FDA

Aldeyra Prepares to Submit Dry Eye Disease Treatment Reproxalap to FDA

BioSpace

Aldeyra Therapeutics

dry eye disease

clinical trials

Flag link:

With lung drug from Pfizer in hand, AN2 tests IPO waters in turbulent market

With lung drug from Pfizer in hand, AN2 tests IPO waters in turbulent market

MedCity News

AN2 Therapeutics

clinical trials

dry eye disease

Flag link:

Aldeyra builds case for troubled dry eye drug reproxalap

Aldeyra builds case for troubled dry eye drug reproxalap

Pharmaforum

Aldeyra Therapeutics

dry eye disease

Flag link:

Why Pfizer Isn't the Big Winner With a Newly Approved Version of Chantix

Why Pfizer Isn't the Big Winner With a Newly Approved Version of Chantix

Motley Fool

dry eye disease

Oyster Point Pharma

Flag link:

FDA OKs an inhaled version of smoking cessation drug Chantix — for a common eye disease

FDA OKs an inhaled version of smoking cessation drug Chantix — for a common eye disease

Endpoints

Oyster Point Pharma

dry eye disease

Flag link:

Aerie CEO exits days after downplaying midphase eye disease flop

Aerie CEO exits days after downplaying midphase eye disease flop

Fierce Biotech

dry eye disease

Flag link:

Aerie touts silver linings from failed PhIIb, plots PhIII in dry eye disease

Aerie touts silver linings from failed PhIIb, plots PhIII in dry eye disease

Endpoints

Aerie Pharmaceuticals

clinical trials

dry eye disease

Flag link:

Oyster Point Pharma Inks Deal with Ji Xing for Dry Eye Disease Therapies

Oyster Point Pharma Inks Deal with Ji Xing for Dry Eye Disease Therapies

BioSpace

Oyster Point Pharma

Ji Xing Pharmaceuticals

dry eye disease

Flag link:

AbbVie revives DTC ads for dry eye med Restasis with a patient front and center

AbbVie revives DTC ads for dry eye med Restasis with a patient front and center

Fierce Pharma

dry eye disease

DTC advertising

Flag link:

Two biotechs target dry eye disease after Novartis’ Xiidra problems

Two biotechs target dry eye disease after Novartis’ Xiidra problems

Pharmaforum

dry eye disease

Azura Ophthalmics

Flag link:

Pages